Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
117
datasets available to search
ShareScore release 0.9.0
Dataset results
117 results for “HIV transmission”
Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns
ClinicalTrials.gov study NCT00006396. IPD Sharing: Not stated. Countries: 1. Publications: 10.
Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors
ClinicalTrials.gov study NCT02738502. IPD Sharing: UNDECIDED. Countries: 1. Publications: 7.
Adapting the HITSystem to Support Prevention of Mother-to-child HIV Transmission
ClinicalTrials.gov study NCT02726607. IPD Sharing: NO. Countries: 2. Publications: 2.
Daily Nevirapine to Prevent Mother to Infant Transmission of HIV
ClinicalTrials.gov study NCT00061321. IPD Sharing: Not stated. Countries: 1. Publications: 18.
Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV
ClinicalTrials.gov study NCT01125696. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding
ClinicalTrials.gov study NCT00640263. IPD Sharing: Not stated. Countries: 4. Publications: 11.
A Study of Nevirapine to Prevent HIV Transmission From Mothers to Their Infants
ClinicalTrials.gov study NCT00001135. IPD Sharing: Not stated. Countries: 2. Publications: 2.
A Study of Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Reduction of Mother-to-child HIV Transmission During Breastfeeding
ClinicalTrials.gov study NCT00146380. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Shortened Zidovudine Regimens to Prevent Mother-to-Child Transmission of HIV Type 1
ClinicalTrials.gov study NCT00386230. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Using Cultural Ceremonies to Reduce Intimate Partner Violence and HIV Transmission
ClinicalTrials.gov study NCT02311699. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention
ClinicalTrials.gov study NCT03870438. IPD Sharing: UNDECIDED. Countries: 2. Publications: 3.
Mathematical Modeling of the HIV Transmission Risk After Initiation of Antiretroviral Therapy in naïve HIV-infected
ClinicalTrials.gov study NCT03183154. IPD Sharing: NO. Countries: 1. Publications: 1.
Routine Use of Antiretroviral Therapy to Prevent Mother-to-Child HIV Transmission in the Kafue District of Zambia
ClinicalTrials.gov study NCT00753324. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Inferring HIV-1 transmission networks and sources of epidemic spread in Africa with deep-sequence phylogenetic analysis
Open the record for dataset details and reuse information.
Data from: A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda
Open the record for dataset details and reuse information.
Phylogenetic analysis of HIV-1 shows frequent cross-country transmission and local population expansions
Open the record for dataset details and reuse information.
Data from: Optimizing prevention of HIV mother to child transmission: duration of antiretroviral therapy and viral suppression at delivery among pregnant Malawian women
Open the record for dataset details and reuse information.
Data from: National-level effectiveness of ART to prevent early mother to child transmission of HIV in Namibia
<p><strong>Background:</strong> Namibia introduced the prevention of mother to child HIV transmission (MTCT) program in 2002 and lifelong antiretroviral therapy (ART) for pregnant women (option B-plus) in 2013. We sought to quantify MTCT measured at 4-12 weeks post-delivery.</p> <p><strong>Methods:</strong> During Aug 2014-Feb 2015, we recruited a nationally representative sample of 1040 pairs of mother and infant aged 4-12 weeks at routine immunizations in 60 public health clinics using two stage sampling approach. Of these, 864 HIV exposed infants had DNA-PCR HIV test results available. We defined an HIV exposed infant if born to an HIV-positive mother with documented status or diagnosed at enrollment using rapid HIV tests. Dried Blood Spots samples from HIV exposed infants were tested for HIV. Interview data and laboratory results were collected on smartphones and uploaded to a central database. We measured MTCT prevalence at 4-12 weeks post-delivery and evaluated associations between infant HIV infection and maternal and infant characteristics including maternal treatment and infant prophylaxis. All statistical analyses accounted for the survey design.</p> <p><strong>Results:</strong> Based on the 864 HIV exposed infants with test results available, nationally weighted early MTCT measured at 4-12 weeks post-delivery was 1.74% (95% confidence interval (CI): 1.00%-3.01%). Overall, 62% of mothers started ART pre-conception, 33.6% during pregnancy, 1.2% post-delivery and 3.2% never received ART. Mothers who started ART before pregnancy and during pregnancy had low MTCT prevalence, 0.78% (95% CI: 0.31%-1.96%) and 0.98% (95% CI: 0.33%-2.91%), respectively. MTCT rose to 4.13% (95% CI: 0.54%-25.68%) when the mother started ART after delivery and to 11.62% (95% CI: 4.07%-28.96%) when she never received ART. The lowest MTCT of 0.76% (95% CI: 0.36% - 1.61%) was achieved when mother received ART and ARV prophylaxis within 72hrs for infant and highest 22.32% (95%CI: 2.78% -74.25%) when neither mother nor infant received ARVs. After adjusting for mother's age, maternal ART (Prevalence Ratio (PR)=0.10, 95% CI: 0.03 – 0.29) and infant ARV prophylaxis (PR=0.32, 95% CI: 0.10 – 0.998) remained strong predictors of HIV transmission.</p> <p><strong>Conclusion:</strong> As of 2015, Namibia achieved MTCT of 1.74%, measured at 4-12 weeks post-delivery. Women already on ART pre-conception had the lowest prevalence of MTCT emphasizing the importance of early HIV diagnosis and treatment initiation before pregnancy. Studies are needed to measure MTCT and maternal HIV seroconversion during breastfeeding.</p>
Viral and Immunologic Factors Contributing to the Lack of HIV Transmission Among Couples in Rakai, Uganda
ClinicalTrials.gov study NCT00342160. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Nevirapine Study for the Prevention of Maternal-Infant HIV Transmission in Uganda
ClinicalTrials.gov study NCT00639938. IPD Sharing: Not stated. Countries: 0. Publications: 5.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.